Trials / Completed
CompletedNCT02492217
Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Universidade Nova de Lisboa · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To identify new candidate genes and proteins that are differentially expressed in responders' vs non-responders to anti-TNF alpha therapy at the several time points the investigators will use the transcriptomic and proteomic analyses. Demonstrate a link between gene expression and protein markers regarding prediction to anti-TNF alpha therapy efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-28
- First posted
- 2015-07-08
- Last updated
- 2020-11-03
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT02492217. Inclusion in this directory is not an endorsement.